Literature DB >> 11739157

Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration.

K W Christopherson1, J J Campbell, R A Hromas.   

Abstract

Chemokines are a large family of cytokines that direct normal leukocyte migration. They also have been implicated in leukocyte development and in the pathogenesis of many diseases. The CC chemokine CCL21, also known as Exodus-2, SLC, 6Ckine, and TCA4 induces both the adhesion and migration of human T cells. CCL21 is hypothesized to regulate the trafficking of T cells through secondary lymphoid tissues. To test this hypothesis, a transgenic mouse model was generated that placed the expression of mouse CCL21 (mCCL21) under the control of the T cell-specific lck promoter to abrogate the concentration gradient to which T cells normally respond. Overexpression of mCCL21 in T cells resulted in defects in CCL21- and CCL19-induced T-cell chemotaxis, node T-cell subpopulations, and lymph node architecture. The regulation of T-cell trafficking in secondary lymphoid tissues by CCL21 is therefore a tightly regulated system that can be altered by changes in the level of environmental CCL21 protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739157     DOI: 10.1182/blood.v98.13.3562

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Transforming growth factor-{beta}1 modulates responses of CD34+ cord blood cells to stromal cell-derived factor-1/CXCL12.

Authors:  Sunanda Basu; Hal E Broxmeyer
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

2.  The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression.

Authors:  Ying Guo; Robert Costa; Heather Ramsey; Trevor Starnes; Gail Vance; Kent Robertson; Mark Kelley; Rolland Reinbold; Hans Scholer; Robert Hromas
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

3.  A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.

Authors:  Yuan Lin; Jie Luo; Weichao Eric Zhu; Minu Srivastava; Dorthe Schaue; David A Elashoff; Steven M Dubinett; Sherven Sharma; Benjamin Wu; Maie A St John
Journal:  Otolaryngol Head Neck Surg       Date:  2014-05-13       Impact factor: 3.497

4.  Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers.

Authors:  Erica M Pimenta; Betsy J Barnes
Journal:  Cancers (Basel)       Date:  2014-04-23       Impact factor: 6.639

5.  Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis.

Authors:  Ingrid Dubois-Vedrenne; Olivier De Henau; Virginie Robert; Francina Langa; Joaquim Javary; Diana Al Delbany; Olivier Vosters; Edgar Angelats-Canals; Maxime Vernimmen; Souphalone Luangsay; Valérie Wittamer; Marc Parmentier
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

6.  Laser capture microdissection and cDNA array analysis of endometrium identify CCL16 and CCL21 as epithelial-derived inflammatory mediators associated with endometriosis.

Authors:  Ashwini L Chand; Andrew S Murray; Rebecca L Jones; Natalie J Hannan; Lois A Salamonsen; Luk Rombauts
Journal:  Reprod Biol Endocrinol       Date:  2007-05-17       Impact factor: 5.211

7.  Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.

Authors:  Karen Riedl; Felicita Baratelli; Raj K Batra; Seok Chul Yang; Jie Luo; Brian Escuadro; Robert Figlin; Robert Strieter; Sherven Sharma; Steven Dubinett
Journal:  Mol Cancer       Date:  2003-11-02       Impact factor: 27.401

8.  Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.

Authors:  Julia Miriam Weiss; Marieke Robinet; Revital Aricha; Perrine Cufi; Bérengère Villeret; Frida Lantner; Idit Shachar; Sara Fuchs; Miriam C Souroujon; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Oncotarget       Date:  2016-02-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.